54 related articles for article (PubMed ID: 16299225)
1. Phosphatidylinositol 3-kinase inhibitors are a triple threat to ovarian cancer.
Parsons R
Clin Cancer Res; 2005 Nov; 11(22):7965-6. PubMed ID: 16299225
[No Abstract] [Full Text] [Related]
2. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.
Hu L; Hofmann J; Jaffe RB
Clin Cancer Res; 2005 Nov; 11(22):8208-12. PubMed ID: 16299254
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).
Hu L; Zaloudek C; Mills GB; Gray J; Jaffe RB
Clin Cancer Res; 2000 Mar; 6(3):880-6. PubMed ID: 10741711
[TBL] [Abstract][Full Text] [Related]
4. The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma.
Zhang L; Yang N; Katsaros D; Huang W; Park JW; Fracchioli S; Vezzani C; Rigault de la Longrais IA; Yao W; Rubin SC; Coukos G
Cancer Res; 2003 Jul; 63(14):4225-31. PubMed ID: 12874030
[TBL] [Abstract][Full Text] [Related]
5. [Expression of phosphatidylinositol-3 kinase in epithelial ovarian carcinoma].
Zhang PN; Sun H
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):196-200. PubMed ID: 17537308
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Mabuchi S; Ohmichi M; Nishio Y; Hayasaka T; Kimura A; Ohta T; Kawagoe J; Takahashi K; Yada-Hashimoto N; Seino-Noda H; Sakata M; Motoyama T; Kurachi H; Testa JR; Tasaka K; Murata Y
Clin Cancer Res; 2004 Nov; 10(22):7645-54. PubMed ID: 15569997
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effect of tirapazamine combined with phosphatidylinositol 3-kinase inhibitor LY294002 to ovarian cancer cells].
Ren Y; Zha X; Zhang GN
Zhonghua Yi Xue Za Zhi; 2007 May; 87(17):1204-6. PubMed ID: 17686243
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
Denlinger CE; Rundall BK; Jones DR
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1422-9. PubMed ID: 16256798
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
[TBL] [Abstract][Full Text] [Related]
11. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.
Garlich JR; De P; Dey N; Su JD; Peng X; Miller A; Murali R; Lu Y; Mills GB; Kundra V; Shu HK; Peng Q; Durden DL
Cancer Res; 2008 Jan; 68(1):206-15. PubMed ID: 18172313
[TBL] [Abstract][Full Text] [Related]
12. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
13. Role of triptolide as an adjunct chemotherapy for ovarian cancer.
Westfall SD; Nilsson EE; Skinner MK
Chemotherapy; 2008; 54(1):67-76. PubMed ID: 18073474
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.
Uddin S; Ahmed M; Hussain A; Assad L; Al-Dayel F; Bavi P; Al-Kuraya KS; Munkarah A
Int J Cancer; 2010 Jan; 126(2):382-94. PubMed ID: 19621391
[TBL] [Abstract][Full Text] [Related]
15. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
[TBL] [Abstract][Full Text] [Related]
16. Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels Y; Diaz LA; Schmidt-Kittler O; Cummins JM; Delong L; Cheong I; Rago C; Huso DL; Lengauer C; Kinzler KW; Vogelstein B; Velculescu VE
Cancer Cell; 2005 Jun; 7(6):561-73. PubMed ID: 15950905
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110alpha inhibitors.
Hayakawa M; Kaizawa H; Moritomo H; Koizumi T; Ohishi T; Okada M; Ohta M; Tsukamoto S; Parker P; Workman P; Waterfield M
Bioorg Med Chem; 2006 Oct; 14(20):6847-58. PubMed ID: 16837202
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
19. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
Kolev VN; Wright QG; Vidal CM; Ring JE; Shapiro IM; Ricono J; Weaver DT; Padval MV; Pachter JA; Xu Q
Cancer Res; 2015 Jan; 75(2):446-55. PubMed ID: 25432176
[TBL] [Abstract][Full Text] [Related]
20. Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production.
Salh B; Wagey R; Marotta A; Tao JS; Pelech S
J Immunol; 1998 Dec; 161(12):6947-54. PubMed ID: 9862729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
